NRIX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Nurix Therapeutics Inc

NASDAQ | NRIX

10.63

USD

(

+0.00%

)

At Close (As of Jan 1, 1970)

$801.13M

Market Cap

-

P/E Ratio

-2.97

EPS

$29.56

52 Week High

$8.18

52 Week Low

HEALTHCARE

Sector

NRIX Chart

Recent Chart
Price Action

NRIX Technicals

Tags:

NRIX Earnings

Yearly Income Statement (As of Nov 30, 2024)

Field Value (USD)
Gross Profit -$167M
Total Revenue $55M
Cost Of Revenue $222M
Costof Goods And Services Sold $222M
Operating Income -$213M
Selling General And Administrative $46M
Research And Development $222M
Operating Expenses $46M
Investment Income Net -
Net Interest Income $20M
Interest Income $20M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $8M
Income Before Tax -$193M
Income Tax Expense $270K
Interest And Debt Expense -
Net Income From Continuing Operations -$194M
Comprehensive Income Net Of Tax -
Ebit -$213M
Ebitda -$205M
Net Income -$194M

Revenue & Profitability

Earnings Performance

NRIX Financials

yearly Balance Sheet (As of Nov 30, 2024)

Field Value (USD)
Total Assets $669M
Total Current Assets $619M
Cash And Cash Equivalents At Carrying Value $110M
Cash And Short Term Investments $110M
Inventory -
Current Net Receivables $1.5M
Total Non Current Assets $50M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $0
Short Term Investments $500M
Other Current Assets $8.3M
Other Non Current Assets -
Total Liabilities $142M
Total Current Liabilities $96M
Current Accounts Payable $11M
Deferred Revenue -
Current Debt -
Short Term Debt $8M
Total Non Current Liabilities $46M
Capital Lease Obligations $28M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $28M
Other Current Liabilities $37M
Other Non Current Liabilities -
Total Shareholder Equity $527M
Treasury Stock -
Retained Earnings -$739M
Common Stock $76K
Common Stock Shares Outstanding $67M

yearly Cash Flow (As of Nov 30, 2024)

Field Value (USD)
Operating Cashflow -$173M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $16M
Capital Expenditures $9.3M
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$258M
Cashflow From Financing $486M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$194M

yearly Income Statement (As of Nov 30, 2024)

Field Value (USD)
Gross Profit -$167M
Total Revenue $55M
Cost Of Revenue $222M
Costof Goods And Services Sold $222M
Operating Income -$213M
Selling General And Administrative $46M
Research And Development $222M
Operating Expenses $46M
Investment Income Net -
Net Interest Income $20M
Interest Income $20M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $8M
Income Before Tax -$193M
Income Tax Expense $270K
Interest And Debt Expense -
Net Income From Continuing Operations -$194M
Comprehensive Income Net Of Tax -
Ebit -$213M
Ebitda -$205M
Net Income -$194M

NRIX Profile

Nurix Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Nurix Therapeutics, Inc. is a San Francisco-based biopharmaceutical company focused on the discovery and development of novel small molecule therapies for cancer and immune disorders. Utilizing its proprietary drug discovery platform, Nurix pioneers targeted protein degradation to develop innovative treatment options aimed at enhancing patient outcomes in oncology and immunology. With a strong commitment to advancing cutting-edge therapeutics, Nurix is well-positioned as a compelling investment opportunity for institutional investors looking to capitalize on transformative advancements in the healthcare sector.

YYAI
+133.74%
$0.18
BYND
-1.10%
$3.58
YDKG
+19.92%
$0.06
BURU
+24.34%
$0.36
VHAI
0.00%
$0.00
ADAP
+49.17%
$0.07
F
-1.03%
$12.43
BENF
+205.95%
$1.49
AIRE
-1.92%
$0.71
CGBS
-39.47%
$0.03
NVDA
-0.48%
$180.28
BITF
-12.24%
$3.94
DNUT
+8.62%
$4.03
RGTI
-9.85%
$36.06
PLUG
-6.41%
$2.92
WTO
+10.81%
$0.07
DNN
0.00%
$2.72
T
-1.91%
$25.55
TLRY
-2.02%
$1.45
INTC
-3.14%
$36.92
TSLA
-0.82%
$438.97
QBTS
-15.22%
$27.29
EPWK
+13.34%
$0.08
RIG
+3.32%
$3.42
SOFI
-5.42%
$27.19
AXDX
-61.36%
$0.03
NOK
-0.53%
$5.55
ACHR
-4.82%
$10.86
CIFR
-10.87%
$16.11
RANI
-15.26%
$2.41
GPUS
+4.79%
$0.38
BBD
0.00%
$3.30
RF
-1.02%
$24.11
AMD
-3.27%
$230.23
IXHL
-2.46%
$0.34
CAN
-12.56%
$1.70
AAL
-2.10%
$12.09
QS
-12.50%
$13.58
PLTR
-3.31%
$175.49
AREB
+72.00%
$2.15
ETHD
+10.21%
$4.09
BNBX
+40.35%
$4.80
NVTS
-9.48%
$13.60
ONDS
-6.25%
$6.74
IREN
-6.09%
$51.83
NIO
+0.58%
$6.84
WBD
+0.98%
$20.53
ABEV
-0.90%
$2.20
QUBT
-7.06%
$14.87
HPE
-0.77%
$23.09
VALE
+2.21%
$11.52
ALEC
-49.84%
$1.61
PFE
-0.52%
$24.72
GRAB
+0.35%
$5.62
IONZ
+13.38%
$4.66
APLD
-5.90%
$30.62
RXRX
-5.89%
$5.75
AAPL
-1.64%
$258.45
BTBT
-7.23%
$3.59
AMZN
-1.83%
$217.95
CJET
+21.50%
$0.09
SOUN
-2.57%
$17.76
JOBY
-3.91%
$15.47
GPRO
+5.00%
$2.31
RR
-10.12%
$5.05
LAES
-11.47%
$5.40
RIVN
-2.12%
$12.92
AVDL
+3.66%
$18.52
SNAP
-1.01%
$7.77
WULF
-3.99%
$12.61
MARA
-4.58%
$19.14
UUUU
+10.22%
$22.74
RMBL
+60.50%
$3.21
IONQ
-6.80%
$55.45
SMR
-9.51%
$34.72
ADD
-25.47%
$0.05
DVLT
-15.41%
$2.14
HOOD
-3.50%
$127.22
BMNR
-7.36%
$48.03
CLSK
-10.17%
$16.86
BTG
+0.57%
$5.21
FLWS
-14.75%
$4.38
AMC
-4.84%
$2.75
GOOGL
+0.49%
$251.69
BAC
-0.81%
$51.10
SRM
+53.27%
$10.30
OKLO
-13.85%
$120.12
SMCI
-4.23%
$52.50
RGTZ
+19.73%
$18.69
VZ
-1.24%
$39.79
PBR
+1.47%
$11.73
VIVK
+7.79%
$0.24
NDLS
+33.01%
$0.95
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
UAMY
+5.81%
$13.11
GSIT
+18.69%
$12.89
ASTS
-9.23%
$71.34
JBLU
-0.85%
$4.62
EOSE
-7.60%
$15.06
YYAI
+133.74%
$0.18
BYND
-1.10%
$3.58
YDKG
+19.92%
$0.06
BURU
+24.34%
$0.36
VHAI
0.00%
$0.00
ADAP
+49.17%
$0.07
F
-1.03%
$12.43
BENF
+205.95%
$1.49
AIRE
-1.92%
$0.71
CGBS
-39.47%
$0.03
NVDA
-0.48%
$180.28
BITF
-12.24%
$3.94
DNUT
+8.62%
$4.03
RGTI
-9.85%
$36.06
PLUG
-6.41%
$2.92
WTO
+10.81%
$0.07
DNN
0.00%
$2.72
T
-1.91%
$25.55
TLRY
-2.02%
$1.45
INTC
-3.14%
$36.92
TSLA
-0.82%
$438.97
QBTS
-15.22%
$27.29
EPWK
+13.34%
$0.08
RIG
+3.32%
$3.42
SOFI
-5.42%
$27.19
AXDX
-61.36%
$0.03
NOK
-0.53%
$5.55
ACHR
-4.82%
$10.86
CIFR
-10.87%
$16.11
RANI
-15.26%
$2.41
GPUS
+4.79%
$0.38
BBD
0.00%
$3.30
RF
-1.02%
$24.11
AMD
-3.27%
$230.23
IXHL
-2.46%
$0.34
CAN
-12.56%
$1.70
AAL
-2.10%
$12.09
QS
-12.50%
$13.58
PLTR
-3.31%
$175.49
AREB
+72.00%
$2.15
ETHD
+10.21%
$4.09
BNBX
+40.35%
$4.80
NVTS
-9.48%
$13.60
ONDS
-6.25%
$6.74
IREN
-6.09%
$51.83
NIO
+0.58%
$6.84
WBD
+0.98%
$20.53
ABEV
-0.90%
$2.20
QUBT
-7.06%
$14.87
HPE
-0.77%
$23.09
VALE
+2.21%
$11.52
ALEC
-49.84%
$1.61
PFE
-0.52%
$24.72
GRAB
+0.35%
$5.62
IONZ
+13.38%
$4.66
APLD
-5.90%
$30.62
RXRX
-5.89%
$5.75
AAPL
-1.64%
$258.45
BTBT
-7.23%
$3.59
AMZN
-1.83%
$217.95
CJET
+21.50%
$0.09
SOUN
-2.57%
$17.76
JOBY
-3.91%
$15.47
GPRO
+5.00%
$2.31
RR
-10.12%
$5.05
LAES
-11.47%
$5.40
RIVN
-2.12%
$12.92
AVDL
+3.66%
$18.52
SNAP
-1.01%
$7.77
WULF
-3.99%
$12.61
MARA
-4.58%
$19.14
UUUU
+10.22%
$22.74
RMBL
+60.50%
$3.21
IONQ
-6.80%
$55.45
SMR
-9.51%
$34.72
ADD
-25.47%
$0.05
DVLT
-15.41%
$2.14
HOOD
-3.50%
$127.22
BMNR
-7.36%
$48.03
CLSK
-10.17%
$16.86
BTG
+0.57%
$5.21
FLWS
-14.75%
$4.38
AMC
-4.84%
$2.75
GOOGL
+0.49%
$251.69
BAC
-0.81%
$51.10
SRM
+53.27%
$10.30
OKLO
-13.85%
$120.12
SMCI
-4.23%
$52.50
RGTZ
+19.73%
$18.69
VZ
-1.24%
$39.79
PBR
+1.47%
$11.73
VIVK
+7.79%
$0.24
NDLS
+33.01%
$0.95
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
UAMY
+5.81%
$13.11
GSIT
+18.69%
$12.89
ASTS
-9.23%
$71.34
JBLU
-0.85%
$4.62
EOSE
-7.60%
$15.06
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.